A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients.
Ther Adv Chronic Dis
; 12: 20406223211039699, 2021.
Article
in English
| MEDLINE | ID: covidwho-1374091
ABSTRACT
OBJECTIVE:
This meta-analysis aims to assess the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies on COVID-19.METHODS:
Relevant literatures about GM-CSF antibody treatment in COVID-19 patients were searched from the PubMed, Cochrane Library, Embase, Google scholar, and Baiduscholar databases from the COVID-19 outbreak in December 2019 until 1 January 2021. The primary outcomes included the death, intensive care unit (ICU) admission risk, ventilation requirement, and secondary infection.RESULTS:
A total of 12 eligible literature involving 8979 COVID-19 patients were recruited, and they were divided into experimental group (n = 2673) and control group (n = 6306). Using a random-effect model, it is found that the GM-CSF antibody treatment was associated with a 23% decline of the risk of death [odd's ratio (OR) 0.34, 95% confidence interval (CI) 0.21-0.56, p < 0.0001] and a 20% enhancement of ventilation (OR 1.47, 95% CI 1.19, 1.80, p = 0.0002). GM-CSF antibody treatment did not have a significant correlation to secondary infection and increased risk of ICU admission in COVID-19 patients, which may be attributed to the older age and the length of stay.CONCLUSIONS:
Severe COVID-19 patients can benefit from GM-CSF antibodies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Language:
English
Journal:
Ther Adv Chronic Dis
Year:
2021
Document Type:
Article
Affiliation country:
20406223211039699
Similar
MEDLINE
...
LILACS
LIS